Subantimicrobial dose doxycycline: A unique treatment for rosacea

Cutis

Volumn 75, Issue 4 SUPPL., 2005, Pages 19-24

  Berman, Brian ^a,b   Zell, Deborah ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b CollaGenex Pharmaceuticals Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZELAIC ACID; BENZOYL PEROXIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLINDAMYCIN; CLONIDINE; COSMETIC; DOXYCYCLINE; ERYTHROMYCIN; ISOTRETINOIN; MACROLIDE; METRONIDAZOLE; MINOCYCLINE; NALOXONE; ONDANSETRON; RETINOIC ACID; SEROTONIN UPTAKE INHIBITOR; SULFACETAMIDE; SULFUR; TETRACYCLINE; TSUKUBAENOLIDE;

ACNE VULGARIS; ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ATHEROSCLEROSIS; BREAST FIBROADENOMA; CARCINOGENIC ACTIVITY; CLINICAL FEATURE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ENDOMETRIUM POLYP; ESOPHAGUS DISEASE; FLUSHING; HEADACHE; HUMAN; HYPERTENSION; INFLAMMATION; LOW LEVEL LASER THERAPY; PAIN; PATHOPHYSIOLOGY; PHARYNGITIS; PHOTOSENSITIVITY; PROTEIN DEGRADATION; PUBLIC HEALTH; RASH; REVIEW; RHINITIS; ROSACEA; SENSITIVITY ANALYSIS; SINUSITIS; THYROID ADENOMA; UPREGULATION; VAGINITIS; VASODILATATION;

ANTI-BACTERIAL AGENTS; DOXYCYCLINE; DRUG RESISTANCE, BACTERIAL; HUMANS; ROSACEA; TREATMENT OUTCOME;

EID: 18244362846     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Feldman SR, Hollar CB, Gupta AK, et al. Women commonly seek care for rosacea: dermatologists frequently provide the care. Cutis. 2001;68:156-160.
2. Bikowski JB. Rosacea: a tiered approach to therapy. Cutis. 2000;66(suppl 4):3-6.
3. Bikowski JB. Subantimicrobial dose doxycycline for acne and rosacea. Skinmed. 2003;2:234-245.
4. Pelle MT, Crawford GH, James WD. Rosacea, II: therapy. J Am Acad Dermatol. 2004;51:499-512.
5. Crawford GH, Pelle MT, James WD. Rosacea, I: etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51:327-341.
6. Lachgar S, Charveron M, Gall Y, et al. Inhibitory effects of retinoids on vascular endothelial growth factor production by cultured human skin keratinocytes. Dermatology. 1999;199(suppl 1):25-27.
7. Gilchrest BA. Treatment of photodamage with topical tretinoin: an overview. J Am Acad Dermatol. 1997;36(suppl 3, pt 2):S27-S36.
8. Bhawan J, Palko MJ, Lee J. Reversible histologic effects of tretinoin on photodamaged skin. J Geriatr Dermatol. 1995;3:62-67.
9. Wilkin JK. Effect of subdepressor clonidine on flushing reactions in rosacea. change in malar thermal circulation index during provoked flushing reactions. Arch Dermatol. 1983;119:211-214.
10. Sadick NS. A structural approach to nonablative rejuvenation. Cosmet Dermatol. December 2002;15:39-43.
11. Dahl MV, Katz HI, Krueger GG, et al. Topical metronidazole maintains remissions of rosacea. Arch Dermatol. 1998;134:679-683.
12. Knight AG, Vickers CF. A follow-up of tetracycline-treated rosacea with special reference to rosacea keratitis. Br J Dermatol. 1975;93:577-580.
13. Food and Drug Administration. Labeling Requirements for Systemic Antibacterial Drug Products Intended for Human Use [final rule]. Rockville, Md: Department of Health and Human Services; Feb 2003. 21 CFR Part 201.
14. Henney JE. FDA perspective on antibiotic resistance. Presented at: Royal Society of Medicine Conference on Antimicrobial Resistance; May 5, 2000; Washington, DC.
15. Eady AH, Cove JH, Layton AM. Is antibiotic resistance in cutaneous Propionibacteria clinically relevant? implications of resistance for acne patients and prescribers. Am J Clin Dermatol. 2003;12:813-831.
16. Ferguson J. Recent trends in prescribing of antibiotics. Prescriber. 2001;12:59-62.
17. Del Rosso JQ, Bikowski J. When an antibiotic is not an antibiotic, current perspectives on subantimicrobial dose doxycycline use in dermatology. Skin Aging. 2004;12:36-42.
18. Data on file. Newton, Pa: CollaGenex Pharmaceuticals, Inc; 2003.
19. Golub LM, Lee HM, Ryan ME, et al. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res. 1998;12:12-26.
20. Skidmore R, Kovach R, Walker C, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol. 2003;139:459-464.
21. Thomas J, Walker C, Bradshaw M. Long-term use of subantimicrobial dose doxycycline does not lead to changes in antimicrobial susceptibility. J Periodontol. 2000;71:1472-1483.
22. Walker C, Thomas J, Nango S, et al. Long-term treatment with subantimicrobial dose doxycycline exerts no antibacterial effect on the subgingival microflora associated with adult periodontitis. J Periodontol. 2000;71:1465-1471.
23. Maibach H. Second-generation tetracyclines, a dermatologic overview: clinical uses and pharmacology. Cutis. 1991;48:411-417.
24. Del Rosso JQ. Systemic therapy for rosacea: focus on oral antibiotic therapy and safety. Cutis. 2000;66(suppl 4):7-13.
25. Minocin [package insert]. Pearl River, NY: Lederle Pharmaceuticals; 1998.
26. Burns FR, Stack MS, Gray RD, et al. Inhibition of purified collagenase from alkali-burned rabbit corneas. Invest Ophthalmol Vis Sci. 1989;30:1569-1575.
27. Periostat [package insert]. Newton, Pa: CollaGenex Pharmaceuticals, Inc; 2003.
28. Bikowski J. New approaches to rosacea therapy. Skin Aging. 2005;13(suppl 2):13-15.
29. Golub LM, Ramamurthy NS, McNamara TF, et al. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med. 1991;2:297-321.
30. Sanchez J. Single-center, randomized, double-blind study of subantimicrobial-dose doxycycline and metronidazole 0.75% lotion for moderate rosacea. Poster presented at: 62nd Annual Meeting of the American Academy of Dermatology; February 6-11, 2004; Washington, DC. P188.
31. Thiboutot D. Efficacy and safety of subantimicrobial-dose doxycycline for the treatment of rosacea. Poster presented at: 63rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005; New Orleans, La. P128.
32. Libby P. Atherosclerosis: the new view. Sci Am. 2002;286:46-55.
33. Brown DL, Desai KK, Vakili BA, et al. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler Thromb Vasc Biol. 2004;24:733-738.